Predictive Oncology (NASDAQ: POAI) on Monday announced that it repaid or extended the secured promissory notes that were due September 28, 2019. POAI repaid the remaining principal and interest balance of $478,590 on one note on September 27th. The company also secured a new investment of $700,000 from a private investor in exchange for a … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Executes Repayments, Extensions of Promissory Notes”
Predictive Oncology (NASDAQ: POAI) is assisting clinicians and researchers in improving outcomes for cancer patients via its AI-driven, tumor-profiling platform. A recent article discussing the company reads, “POAI’s technology combines its database of evidence documenting actual drug responses of cancer patients’ tumors with artificial intelligence (AI) to create an invaluable predictive tool for clinicians and … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Precision Medicine Tools to Physicians”
Predictive Oncology (NASDAQ: POAI) is taking a unique approach to cancer treatment by utilizing its proprietary database of cancer cases using the proven power of artificial intelligence (“AI”). A recent article discussing the company reads, “The company works alongside pharmaceutical, diagnostic and biotechnology industry players to develop highly customizable assessment methods that can be applied … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Transforming Cancer-Treatment Outcomes via Proprietary Database”
POAI’s artificial intelligence (AI)-driven tumor profiling platform brings precision medicine tools to clinicians and researchers to improve cancer outcomes The company holds a critical strategic advantage over mammoth competitors, attracting investor attention POAI is committed to providing sophisticated tools to help select current therapies more precisely and develop new targeted therapies Predictive Oncology Inc. (NASDAQ: … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Uses Smart Tumor Profiling Platform with AI to Bring Value to Pharmaceutical, Biotech Industries”
Predictive Oncology is working to develop highly customizable assessment methods to individualize treatment options for cancer, improving outcomes POAI’s innovative technology is pioneering in the field of individualizing treatment for ovarian cancer Predictive Oncology offers potential for significant ROI as it focuses on improving outcomes for cancer patients of today and tomorrow Predictive Oncology Inc. … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Utilizes Proprietary Dataset to Revolutionize Treatment Outcomes for Cancer”
Data and artificial intelligence-driven discovery services company Predictive Oncology (NASDAQ: POAI) provides predictive models of tumor drug response to improve patient outcome. A recent article discussing the company reads, “Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted … Continue reading “NetworkNewsBreaks – Why Predictive Oncology Inc. (NASDAQ: POAI) Is ‘One to Watch’”
Helomics is collaborating with the University of Pittsburgh School of Medicine to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients. More than 22,000 women are diagnosed with ovarian cancer in the U.S. each year. Entered an agreement with Interpace Diagnostics Group Inc. (IDXG) and Helomics to develop products … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) is “One to Watch””
Predictive Oncology (NASDAQ: POAI) is focused on the use of data and artificial intelligence (AI) to develop personalized cancer therapies, which can lead to more effective treatments and improved patient outcomes. The company has several tools that support its mission of bringing precision medicine to the diagnosis of cancer. Through its subsidiaries, Predictive Oncology’s portfolio … Continue reading “Predictive Oncology (NASDAQ: POAI)”
Predictive Oncology Inc. (NASDAQ: POAI), an artificial intelligence (AI) and data-driven functional precision medicine company, this morning announced that it will report its financial results for the fiscal quarter ended June 30, 2019, after market close today, August 19. Per the update, the company’s management team will host a conference call to review the financial … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) to Report Q2 2019 Results, Host Conference Call after Market Close”
Predictive Oncology’s (NASDAQ: POAI) subsidiary Helomics in July announced a joint collaborative agreement with the University of Pittsburgh School of Medicine (“UPMC”) to study the use of Helomics’ artificial intelligence (“AI”) platform (D-CHIP)(TM) to improve clinical decision making for ovarian cancer patients. The platform will be employed to analyze the genomic and drug response profiles … Continue reading “NetworkNewsBreaks – Predictive Oncology, Inc. (NASDAQ: POAI) Subsidiary Partners with UPMC to Develop AI-Powered Method to Treat Ovarian Cancer”
